PL3664800T3 - Preparaty terapeutyczne zawierające inhibitor cox-2 i ich zastosowania - Google Patents

Preparaty terapeutyczne zawierające inhibitor cox-2 i ich zastosowania

Info

Publication number
PL3664800T3
PL3664800T3 PL18843332.0T PL18843332T PL3664800T3 PL 3664800 T3 PL3664800 T3 PL 3664800T3 PL 18843332 T PL18843332 T PL 18843332T PL 3664800 T3 PL3664800 T3 PL 3664800T3
Authority
PL
Poland
Prior art keywords
cox
inhibitor
therapeutic formulations
formulations
therapeutic
Prior art date
Application number
PL18843332.0T
Other languages
English (en)
Inventor
Douglas Hepler
Gail L. Dempsey
Roland Johnson
Michael Kelly
Michael Daniel
Neil E. Paulsen
Bert CLAYTON
Original Assignee
Dechra Veterinary Products, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dechra Veterinary Products, Llc filed Critical Dechra Veterinary Products, Llc
Publication of PL3664800T3 publication Critical patent/PL3664800T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18843332.0T 2017-08-09 2018-08-09 Preparaty terapeutyczne zawierające inhibitor cox-2 i ich zastosowania PL3664800T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543215P 2017-08-09 2017-08-09
US201762594399P 2017-12-04 2017-12-04
PCT/US2018/046130 WO2019032910A1 (en) 2017-08-09 2018-08-09 THERAPEUTIC FORMULATIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
PL3664800T3 true PL3664800T3 (pl) 2024-11-18

Family

ID=65272625

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18843332.0T PL3664800T3 (pl) 2017-08-09 2018-08-09 Preparaty terapeutyczne zawierające inhibitor cox-2 i ich zastosowania

Country Status (13)

Country Link
US (3) US20190142789A1 (pl)
EP (2) EP4389147A3 (pl)
JP (2) JP2020530462A (pl)
AU (2) AU2018313933B2 (pl)
CA (1) CA3072335A1 (pl)
DK (1) DK3664800T3 (pl)
ES (1) ES2984268T3 (pl)
FI (1) FI3664800T3 (pl)
HR (1) HRP20241063T1 (pl)
HU (1) HUE068027T2 (pl)
PL (1) PL3664800T3 (pl)
PT (1) PT3664800T (pl)
WO (1) WO2019032910A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233854A3 (en) * 2019-11-01 2024-01-17 Piedmont Animal Health Inc. Therapeutic formulations and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
NZ270145A (en) * 1994-03-01 1996-08-27 Lilly Co Eli Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
GB9804886D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
US20040105885A1 (en) * 2001-04-17 2004-06-03 Ping Gao Gelatin capsule exhibiting reduced cross-linking
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20040138296A1 (en) * 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050107349A1 (en) * 2003-07-24 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
JP2007528384A (ja) * 2004-03-10 2007-10-11 シモダ、バイオテック(プロプライエタリー)リミテッド 安定な注射可能なジクロフェナク組成物
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Fgf−20の調合物、生成方法および使用
EP2089010A1 (en) * 2006-10-24 2009-08-19 The John Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
WO2010128095A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Ectoparasiticidal compositions
EP2608771B1 (en) * 2010-08-23 2018-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions for gastric delivery of active agents
CN103889414A (zh) * 2011-10-18 2014-06-25 拉夸里亚创药株式会社 药物组合物
AU2013338098B2 (en) * 2012-10-30 2018-03-15 Nektar Therapeutics Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2016201259A1 (en) * 2015-06-10 2016-12-15 Piedmont Pharmaceuticals Llc Injectable antibiotic formulations and use thereof
WO2018165477A1 (en) * 2017-03-10 2018-09-13 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof
WO2018226677A1 (en) * 2017-06-05 2018-12-13 Piedmont Animal Health, Llc Long-acting non-aqueous injectable formulations and use thereof

Also Published As

Publication number Publication date
EP4389147A3 (en) 2024-10-23
AU2024203213A1 (en) 2024-05-30
WO2019032910A1 (en) 2019-02-14
CA3072335A1 (en) 2019-02-14
JP2023134739A (ja) 2023-09-27
JP2020530462A (ja) 2020-10-22
AU2018313933A1 (en) 2020-03-12
DK3664800T3 (da) 2024-07-22
FI3664800T3 (fi) 2024-08-07
EP3664800A4 (en) 2021-09-01
HUE068027T2 (hu) 2024-12-28
US20230285354A1 (en) 2023-09-14
US20240100014A1 (en) 2024-03-28
PT3664800T (pt) 2024-08-14
EP3664800A1 (en) 2020-06-17
EP4389147A2 (en) 2024-06-26
ES2984268T3 (es) 2024-10-29
US20190142789A1 (en) 2019-05-16
EP3664800B1 (en) 2024-05-08
AU2018313933B2 (en) 2024-03-07
HRP20241063T1 (hr) 2024-11-08

Similar Documents

Publication Publication Date Title
IL262387A (en) Arginase inhibitors and their treatment applications
ZA202002172B (en) Pde9 inhibitor and use thereof
EP3324967A4 (en) PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
PT3638251T (pt) Formulações de gel de bifosfocina e suas utilizações
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
LT3621694T (lt) Lrrc33 inhibitoriai ir jų panaudojimas
IL273339A (en) Griseofulbin compound and its medical use
GB201715194D0 (en) Compounds and their therapeutic use
IL266132B (en) Pharmaceutical formulations and methods for their preparation
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
IL268583A (en) Preparations and methods for use on the skin
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
IL291543A (en) Medical preparations and their use
IL274433A (en) Fulvestrant formulations and methods of using them
EP3497080A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR USE
ZA201908264B (en) Formulations of homotaurines and salts thereof
HUE068027T2 (hu) COX-2 inhibitort tartalmazó terápiás készítmények és alkalmazásuk
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201818904D0 (en) New formulations and methods
IL282671A (en) Therapeutic methods and compositions
GB201816605D0 (en) New formulations and uses thereof
HK40039258A (en) Cytobiologics and therapeutic uses thereof